100% position for 4 years, earliest starting date: 1 January 2027
This PhD project develops ultrasmall, intravenously deliverable hafnium oxide nanoparticles to improve radiotherapy for high-risk neuroblastoma, a pediatric cancer with poor prognosis and limited treatment options.
Neuroblastoma remains a major unmet clinical need because high-risk disease is still associated with poor outcomes despite multimodal treatment, while conventional radio-chemotherapy is constrained by toxicity to healthy tissue. Radiotherapy-enhancing nanoparticles offer a promising route to increase local tumor damage without simply escalating X-ray dose. Hafnium oxide nanoparticles are attractive radioenhancers because hafnium strongly absorbs X-rays, leading to enhanced local energy deposition and free-radical generation during irradiation. Clinical studies have already demonstrated the translational potential of this approach, but current strategies rely on direct intratumoral injection of relatively large particles, which limits treatment to accessible tumors.